

THERAPEUTIC AGENTS FOR ACHONDROPLASIA

ABSTRACT OF THE DISCLOSURE

The present invention aims to provide novel  
5 therapeutic agents for achondroplasia caused by mutations  
in FGFR3.

Therapeutic agents for achondroplasia caused by the  
cartilage growth inhibition resulting from mutations in the  
gene for fibroblast growth factor receptor 3 (FGFR3),  
10 comprising a substance activating guanylyl cyclase B (GC-B)  
as an active ingredient are disclosed.